1-环戊基-1H-吡咯 | 752205-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-环戊基-1H-吡咯
• 英文名称: N-cyclopentylpyrrole
• 英文别名: 1-Cyclopentyl-1H-pyrrole；1-cyclopentylpyrrole
• CAS: 752205-97-3
• 化学式: C₉H₁₃N
• mdl: MFCD12187094
• 分子量: 135.209
• InChiKey: RAOWKEURONKRKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  215.2±9.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-环戊基-1H-吡咯 、 在 三乙胺 作用下， 以 异丙醇 为溶剂， 反应 0.17h， 以155 mg的产率得到12-(1-cyclopentyl-1H-pyrrol-2-yl)-8-methoxy-12Hchromeno[2,3-c]isoquinolin-5-amine
  参考文献：
  名称：

  Microwave-assisted sequential three-component synthesis of pyrrolyl-substituted chromeno[2,3-c]isoquinolin-5-amines

  摘要：

  Sequential one-pot domino reaction of homophthalonitrile, salicylaldehydes, and pyrroles in basic media under MW irradiation results in the formation of novel chromeno[2,3-c]isoquinolin-5-amines. The transformation represents a domino sequence that starts with Knoevenagel condensation, followed by two nucleophilic cyclizations, consecutively forming 2-iminochromene and 5-iminoisoquinoline cycles. Michael addition of the pyrrole unit to the chromene cycle finishes the transformation. The reaction tolerates various salicylaldehydes and pyrroles, producing target molecules with good 45-67% yields.

  DOI：

  10.1007/s10593-020-02686-5
• 作为产物：
  描述：

  2,5-二甲氧基四氢呋喃 、 环戊胺 在 iron(III) chloride hexahydrate 作用下， 以 水 为溶剂， 以80%的产率得到1-环戊基-1H-吡咯
  参考文献：
  名称：

  Iron-Catalyzed Inexpensive and Practical Synthesis of N-Substituted Pyrroles in Water

  摘要：

  一种操作简便、实用且经济的实验方案已被开发，用于在水相中以铁(III)氯化物为催化剂进行Paal-Knorr吡咯合成，产率良好至优异。在非常温和的反应条件下，多个N-取代吡咯可以方便地通过2,5-二甲氧基四氢呋喃与芳基/烷基、磺酰基和酰基胺的反应来制备。

  DOI：

  10.1055/s-0029-1217799

文献信息

• [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152018A1

  公开（公告）日：2014-09-25

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了具有以下结构的八氢环戊吡咯化合物：(结构表示) 其中psi为不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C(O)或C(O)NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H，其中当B为CO2H时，A存在且为C(O)；且当psi存在时，R6不存在，当psi不存在时，R6存在，或其药用可接受盐，用于治疗以视网膜过度脂褐素积聚为特征的疾病。
• [EN] NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ ROR-GAMMA
  申请人：BIOGEN IDEC INC

  公开号：WO2014028669A1

  公开（公告）日：2014-02-20

  The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases.

  本发明涉及芳基砜和相关化合物，它们是ROR-gamma受体的调节剂。该发明还提供包含这些调节剂的药物组合物，以及使用它们调节ROR-gamma受体的方法。还提供了使用芳基砜和相关化合物作为ROR-gamma调节剂治疗ROR-gamma介导疾病的方法。
• Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：Ortuno Jean-Claude

  公开号：US20110034460A1

  公开（公告）日：2011-02-10

  Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO 2 group, R 1 and R 2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R 3 and R 4 , together with the atoms carrying them, form a heterocyclic group, R 5 represents a hydrogen atom or an alkyl group, R 6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

  式（I）的化合物： 其中： m和n代表1或2， A代表吡咯基， X代表C（O）、S（O）或SO2基团， R1和R2代表烷基或与携带它们的氮原子一起形成杂环基团， R3和R4与携带它们的原子一起形成杂环基团， R5代表氢原子或烷基， R6代表氢原子或卤素原子。 含有这些化合物的药物，可用于治疗癌症。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20170015655A1

  公开（公告）日：2017-01-19

  The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供一种具有HDAC抑制作用的杂环化合物，用于治疗自身免疫疾病和/或炎症性疾病、移植物抗宿主病、癌症、包括神经退行性疾病、沙科-玛丽-图特病等在内的中枢神经疾病，以及包含该化合物的药物组合物。本发明涉及一种由下式（I）表示的化合物： 其中每个符号如规范中定义，或其盐。
• METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150099875A1

  公开（公告）日：2015-04-09

  The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.

  本发明涉及通过顺序亲核芳香取代法合成2,4-二取代嘧啶的新颖区域选择性合成。